Kasper Roet is the founder of QurAlis. QurAlis has raised $144M in total funding. Latest round: Series B. Based in Cambridge, MA.
Kasper Roet is the CEO and co-founder of QurAlis, a clinical-stage biotech company focused on amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. He co-founded QurAlis in 2018 with a specific focus on neurodegenerative diseases, particularly ALS and genetically-related frontotemporal dementia (FTD). Roet has a long-standing interest in developing therapies for neurodegenerative diseases and was motivated by advancements in AI-based identification of genetic underpinnings of ALS, making it a tractable problem for intervention.
Full founder directory · Investor directory · Company funding database · Fundraising library